| P50 | author | Teun Bousema | Q44168464 |
| | Katharine A Collins | Q55175774 |
| | Isaie J Reuling | Q56384676 |
| | Robert Sauerwein | Q72530989 |
| P2093 | author name string | Matthew Adams | |
| | James S McCarthy | |
| | Jörg J Möhrle | |
| | Hayley Mitchell | |
| | Stephan Chalon | |
| | Suzanne Elliott | |
| | Melanie Rampton | |
| | Claire Yt Wang | |
| P2860 | cites work | A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs | Q28476638 |
| | Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers | Q28482471 |
| | Inferring developmental stage composition from gene expression in human malaria | Q28536897 |
| | High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria | Q28829342 |
| | Genesis, sequestration and survival of Plasmodium falciparum gametocytes: parameter estimates from fitting a model to malariatherapy data | Q30665506 |
| | Initiation of gametocytogenesis at very low parasite density in Plasmodium falciparum infection. | Q33662226 |
| | Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study | Q33732740 |
| | A Research Agenda to Underpin Malaria Eradication | Q33818020 |
| | Molecular Markers for Sensitive Detection of Plasmodium falciparum Asexual Stage Parasites and their Application in a Malaria Clinical Trial | Q33901814 |
| | Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. | Q33974904 |
| | Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination | Q34177472 |
| | Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission | Q36215894 |
| | Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial | Q36427654 |
| | High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission | Q36492518 |
| | NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections | Q36547334 |
| | Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection | Q36864852 |
| | Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01 | Q36871970 |
| | Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia. | Q37003081 |
| | Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers | Q37193141 |
| | A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study | Q37254756 |
| | Controlled human blood stage malaria infection: current status and potential applications | Q38001604 |
| | Experimentally induced blood stage malaria infection as a tool for clinical research. | Q38049896 |
| | Building an effective malaria vaccine pipeline to address global needs | Q38607840 |
| | Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay | Q38845963 |
| | Biology of Malaria Transmission | Q39005901 |
| | Quantification of female and male Plasmodium falciparum gametocytes by reverse transcriptase quantitative PCR. | Q39438001 |
| | Sexual Development of Malarial Parasites | Q40093039 |
| | Experimental study of the relationship between Plasmodium gametocyte density and infection success in mosquitoes; implications for the evaluation of malaria transmission-reducing interventions | Q41581139 |
| | A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers | Q41832478 |
| | Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward | Q44144794 |
| | Experimental human challenge infections can accelerate clinical malaria vaccine development | Q44156054 |
| | A Molecular Assay to Quantify Male and Female Plasmodium falciparum Gametocytes: Results From 2 Randomized Controlled Trials Using Primaquine for Gametocyte Clearance | Q44168409 |
| | Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. | Q44171862 |
| | Effects of anticoagulants on Plasmodium vivax oocyst development in Anopheles albimanus mosquitoes | Q44173151 |
| | Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria | Q44903369 |
| | Hy's law: predicting serious hepatotoxicity | Q82907987 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria transmission | Q56928847 |
| P304 | page(s) | 1551-1562 | |
| P577 | publication date | 2018-03-12 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | A controlled human malaria infection model enabling evaluation of transmission-blocking interventions | |
| P478 | volume | 128 | |